|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.05 USD | -3.12% |
|
+12.99% | +12.30% |
| 01-11 | Beam Therapeutics sets strategic priorities for its genetic disease & hematology franchises | RE |
| 01-07 | UBS Initiates Beam Therapeutics at Neutral With $28 Price Target | MT |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 15 | |||||||
| 22 | |||||||
| 20 | |||||||
| 25 | |||||||
| 22 | |||||||
| 19 | |||||||
| 12 | |||||||
| 15 | |||||||
| 16 | |||||||
| 15 | |||||||
| 22 | |||||||
| 12 | |||||||
| 12 | |||||||
| 14 | |||||||
| 5 | |||||||
| 13 | |||||||
| - | - | ||||||
| 15 | |||||||
| 11 | |||||||
| Average | 16 | |||||||
| Weighted average by Cap. | 18 |
- Stock Market
- Equities
- BEAM Stock
- Sector Beam Therapeutics Inc.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition